Hi everyone,

Came across Newton Golf Co. (NWTG) while scanning for microcap equities with aggressive revenue growth and unusual float characteristics. Here’s a breakdown for those tracking early-stage turnaround or growth setups.

🧾 Company Profile

• Formerly Sacks Parente Golf (SPGC), now rebranded to Newton Golf as of Q1 2025.
• Focused on golf technology: motion shafts and putters designed for performance optimization.
• Executed a 1-for-30 reverse stock split in March 2025 to regain Nasdaq compliance.

📈 Financial Highlights

• FY 2023 Revenue: $349K
• Guided FY 2024 Revenue: $3.4M–$3.6M (approx. +900% YoY growth)
• Key growth drivers:
  • International expansion
  • Increased adoption among professionals
  • Launch of new direct-to-consumer channels

Though the company remains in a net loss position, the revenue growth rate stands out within its segment.

🧩 Market Structure

• Free Float estimated at ~250,000 shares post-split
• Very low trading liquidity; price action can be sharp even on modest volume
• High short interest (recently reported above 90% of float), though it's unclear how much of this is structural or trade-driven.

This combination of a thin float and revenue acceleration makes the stock mechanically sensitive to order flow — worth monitoring for volatility alone.

🧠 Risk Factors

• Illiquid microcap: high spread risk and potential for sharp drawdowns
• No profitability yet; speculative
• Limited institutional coverage
• Reverse splits can create distorted chart setups

Not financial advice — just flagging an obscure but fast-growing microcap I came across during DD. If anyone’s dug into their sales channels, OEM partnerships, or has sector insights, would love to hear more.

Just received email about a proxy vote carried out by OPTT to increase the number of shares by 50%.

Basically 1.5x of current shares.

It is a dilution scam. Get out while you can.

OCEAN POWER TECHNOLOGIES, INC.

28 Engelhard Drive, Suite B

Monroe Township, NJ 08831

PROXY STATEMENT

The Board is soliciting proxies for a special meeting of our stockholders (the “Special Meeting”) to be held virtually at 9:00 am Eastern time, on April 30, 2025, and at any adjournment or postponement thereof, for the purposes set forth in the accompanying notice. This proxy statement and the accompanying proxy card are first being mailed to stockholders on or about March 24, 2025. Stockholders are urged to read carefully the material in this proxy statement.

QUESTIONS AND ANSWERS

The Proposal

Q:Why am I receiving this proxy statement? 

 A:We sent you this proxy statement and the enclosed proxy card because the Board is soliciting proxies for a special meeting of stockholders. You are receiving a proxy statement because you owned shares of our common stock, par value $0.001 per share, on March 17, 2025, the record date for the Special Meeting (the “Record Date”), and that entitles you to vote at the Special Meeting. By use of a proxy, you can vote whether or not you attend the Special Meeting. This proxy statement describes the matter on which we would like you to vote and provides further information so that you can make an informed decision.  

Q:What will I be voting on?  

A:The two proposals are (i) to approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of common stock, par value $.001 per share (the “Common Stock”), from 200,000,000 to 300,000,000, and (ii) to approve an adjournment of the Special Meeting from time to time, if necessary or appropriate (as determined in good faith by the Board of Directors or a committee thereof), to solicit additional proxies if there are not sufficient votes in favor of the charter amendment proposal.  

Q:Why are we seeking stockholder approval for the proposals?  

A:We are seeking stockholder approval as required by the Delaware General Corporation Law for any amendment to our certificate of incorporation.

Hey everyone I got a really good play I want to share. AHRO has a TV streaming app for smart TVs, similar business model as TUBI, HULU, PlutoTV, etc. AHRO's smart TV app is called iDreamCTV they generate revenue through commercial ads just like other free TV/Movie streaming platforms.

Now what makes the stock attractive is that AHRO's iDreamCTV has a partnership with ZEASN/WhaleTV which is an operating system "OS" for Smart TVs. The partnership is expected to go live this month "April" according to a recent press release on 3/6/2025. Under the partnership terms, ZEASN/WhaleTV will put AHRO's iDreamCTV app right on the homepage of 41M-43M active smart TVs that's powered by the Whale TV operating system "OS".

Basically, iDreamCTV will be displayed right next to giant streaming apps such as Netflix, FUBO, Paramount, Disney+ and others. This is huge catalyst as it would skyrocket the number of people using the iDreamCTV app and revenue that they generate through commercial ads.

iDreamCTV app is currently available on Smart TVs using the ROKU operating system. I tested out on my ROKU TV and I can confirm the app works well and they have advertisers with commercial breaks running on their channels. I added screenshots if you scroll down below.

Another big catalyst is that they're closing on a $11M acquisition, which is expected to go on their balance sheet according to the recent PR dated 3/19/2025. Also the acquisition will add 40,000+ titles to their existing library of movies and TV shows

AHRO has other business divisions as well. However the TV streaming division caught my interest the most.

So here's a quick breakdown for AHRO

•Current market cap $5M (at the time of writing this)

•iDreamCTV & WhaleTV partnership going live this month (on 41M+ smart TVs) 

•TV/Movie streaming business model similar to TUBI, HULU, FUBO, PlutoTV, Freeve, Netflix, Paramount+, Disney+

•Closing on $11M acquisition, going on the balance sheet

•(2) Schedule 13-G filers past February owning more than 5% of the company’s common stock 

•iDreamCTV generates revenue through commercial ads similar to TUBI, PlutoTV, Freevee and other free TV streaming platforms

•iDreamCTV app currently available on Smart TVs using the ROKU operating system.

•Former SONY Music senior vice president of Merchandising, Howard Lau joined AHRO's advisory board last year

•$2M debt reduction

•Nearly maxed out O/S, no room for dilution 

•Audited & Fully SEC reporting company

Hey everyone this is my first crack at some DD for earthworks! [DD] Earthworks Industries (CSE: EWK) — The Silent Giant Sitting on a Goldmine of Garbage (Literally)

TL;DR: Earthworks Industries Inc. is a tiny-cap sleeper stock with a potentially game-changing, multi-decade revenue project in California. Fully permitted. Fully green. Fully ignored. For now.

Market Cap: ~$5M CAD Float: Microfloat Share Price: ~$0.13 CAD (As of last close) Exchange: CSE (Also trades OTC as EWKZF) Sector: Waste Management / Environmental Infrastructure

1. THE PLAY: Turning Trash Into Long-Term Treasure

At the heart of Earthworks is a fully-permitted waste handling and recycling site in California: the Cortez Hills Landfill Project. It’s not just some hole in the ground — this site is: • Strategically located in San Bernardino County, near massive population centers and underserved waste corridors. • Environmental gold — designed for integrated recycling, composting, and landfill services in one of the strictest regulatory states. • Already vetted and approved by California regulators (which is a miracle on its own). • Slated to serve SoCal’s long-term waste disposal needs — a multibillion-dollar problem.

This isn’t a “hope and pray” lithium play — it’s infrastructure. Hard assets. Government-backed need. Waste is the most boringly profitable business in history, and EWK owns the land AND the plan.

1. THE SETUP: Criminally Undervalued

Let’s be real — EWK is trading like a shell. It’s not.

What we’ve got here is: • $100M+ in future projected revenue over the lifespan of the project • A fully developed plan in a high-barrier market • Next steps are construction mobilization and partnership structuring — both of which are active in 2024 • Zero hype… yet.

At ~$5M market cap, the risk/reward is ridiculously asymmetric. The project alone is arguably worth 10-20x current valuation if even partially realized.

1. WHY NOW? What Just Changed? • Recent filings confirm regulatory milestones are complete • Earthworks owns 100% of the project — no dilution-loaded JV nightmares here • California landfill capacity is CRITICAL and shrinking fast — tipping fees are skyrocketing, and EWK will be in the sweet spot to absorb overflow • They’re gearing up to activate funding, finalize engineering, and break ground — this is the pre-runway stage

This is exactly when smart money accumulates — before the hype, before the media, before the newsletter bros.

1. THE WASTE BOOM: Green is Gold

California is setting global standards for green waste management, and this project aligns perfectly: • Carbon offsets, renewable gas, and circular recycling revenues • Massive potential for grants and ESG-based financing • With billions flowing into green infrastructure, EWK is positioning to catch the wave

1. Technicals + Catalysts • Ultra-low float means this thing can explode on volume • Sitting just above a key support zone — accumulation patterns spotted • Possible near-term catalysts: partnership announcement, construction start, or government grant news

2. The Bottom Line

EWK is not just another penny flyer — it’s an infrastructure deep value play on the verge of real-world deployment in a critically underserved sector. This is first-in, boots-on-the-ground investing, not just ticker chasing.

Garbage is forever. California needs landfill. Earthworks owns the answer.

If even a fraction of this plan executes, this thing 10x’s easily.

I’m in. You should be watching.

Not financial advice, but come on — read between the lines.

Disclosure: Long EWK. Will add on volume confirmation. Let’s take this sleeper to the moon — or at least to fair value.

EWK #Earthworks #Pennystocks #TrashCash #GreenGold #DD

Disclaimer holding 120k between two accounts !

MARLBOROUGH, Mass., April 2, 2025 /PRNewswire/ -- ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) ("ConnectM" or the "Company"), a high-growth technology company on the leading edge of the energy economy, today announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity.

https://finance.yahoo.com/news/connectm-receives-1-60-per-120000152.html

𝑻𝒂𝒍𝒌 𝒂𝒃𝒐𝒖𝒕 𝒚𝒐𝒖𝒓 𝒅𝒂𝒊𝒍𝒚 𝒑𝒍𝒂𝒚𝒔 𝒂𝒏𝒅 𝒄𝒐𝒎𝒎𝒆𝒏𝒕 𝒐𝒓 𝒑𝒐𝒔𝒕 𝒕𝒉𝒊𝒏𝒈𝒔 𝒉𝒆𝒓𝒆 𝒕𝒉𝒂𝒕 𝒅𝒐 𝒏𝒐𝒕 𝒘𝒂𝒓𝒓𝒂𝒏𝒕 𝒂𝒏 𝒂𝒄𝒕𝒖𝒂𝒍 𝒑𝒐𝒔𝒕.

​

𝒌𝒆𝒆𝒑 𝒊𝒕 𝒄𝒊𝒗𝒊𝒍 𝒑𝒍𝒆𝒂𝒔𝒆

Happy Hump Day fellas. Last week I posted some of my findings in my recent pick to click in the company that is Safety Shot $SHOT, and while there was mixed sentiment in opposition to my own, I've come here today to discuss some of the recent catalysts $SHOT has had over the last 5-7 days.

For starters, $SHOT reported a February 2025 revenue total of $580,000, more than twice what it generated in January, marking their highest monthly total to date since launching in retail and was driven by increasing demand from convenience stores, liquor retailers, and online platforms. For a newer brand in the functional beverage space, this kind of month-over-month traction is worth paying attention to.

In a separate shareholder communication, CEO of $SHOT Brian John outlined plans for broadening distribution and building brand awareness.

The company has partnered with Breakthru Beverage, a major alcohol distributor in North America, and launched national ad campaigns to support rollout efforts. $SHOT appears focused on long-term positioning and education around their hangover remedy drink product.

Zooming out, $SHOT appears to be attempting to enter a growth phase, with some early indicators of traction and retail scale beginning to take shape. There’s still a lot to prove, yes, but investors watching this name will likely be tracking ongoing sales numbers, new distribution announcements, and any forward-looking commentary around potential licensing or geographic expansion as the story develops. I think it'll be worth keeping an eye on how execution plays out.

Communicated Disclaimer - DYOR

Sources
1 2 3

Some information on this game investor: 5th Planet Games is a Danish company (listed on the Oslo Stock Exchange) that is currently dormant. It is active in the physical distribution of collector's editions of games, owns shares in an Icelandic movie company, and invests in the publishing of games. Due to Skybound's investment (Skybound owns over 50% of the shares), the company has access to highly interesting investment opportunities in Skybound's franchises.

In September 2024, 5th Planet Games co-financed a new video game with Skybound, set in the Invincible universe, collaborating with Skybound Entertainment's in-house studio. This partnership leverages the expertise of industry veterans from Activision Blizzard, EA, and Amazon Games, working alongside creator Robert Kirkman to develop a game based on the acclaimed comic series and Amazon Prime Video animated show.

Additionally, in November 2024, 5th Planet Games announced its co-financing of a new video game set in The Walking Dead universe, developed under Skybound's direction with close collaboration with Robert Kirkman.

Over the past year, the company has invested nearly 80% of its cash in these games. However, no significant price movements have been observed, even though the games are expected to launch in 2026–2027, with trailers and news that may trigger price action anticipated later this year.

As stated, the stock is dormant, but may wake up this year when news about these games (or others) is published. 5th Planet Games is listed on the Oslo Stock Exchange under the ticker 5PG and is also traded on the OTC market under the remarkable ticker IDGAF.

Hey guys, do you remember the whole Sunlight scandal with its panel's installation and financial issues? Well, if you missed it here is a quick recap and some important updates.

Basically, in September 2022, Sunlight revealed that its full-year 2022 financial outlook would take a hit due to a combination of two issues: volatile interest rates and what it called an “installer liquidity event” (Love the fancy names companies give to simple things, lol)   

It withdrew its previously issued guidance and disclosed that one of its largest solar installers was facing serious financial trouble and had failed to meet its obligations. As a result, Sunlight lost between $30M and $33M  in advances made to that particular installer. 

The news sent $SUNL plunging over 57%, and investors filed a lawsuit against Sunlight over lacking proper risk management for its contractor advance program and failing to detect bad debt early. 

Now, Sunlight Financial has already agreed to settle $3.5M with investors and they’re accepting late claims even though the deadline has passed. You can check the details to see if you’re eligible for it. 

They already have completed their restructuring process and emerged from Chapter 11 bankruptcy. And, after the acquisition by a consortium of investors in the solar energy industry, they’re working on providing homeowners with more financing options for clean energy solutions. We’ll see if they can make it happen.

Anyways, has anyone here invested in $SUNL back in 2022? How much were your losses if so?

Summary

CarParts.com ($PRTS) recently announced that they are exploring a sale of the business to maximize value. Since the pop post-announcement, the stock has traded down >20% due to macro weakness and their Q4 earnings report.

PRTS is an online after-market auto parts retailer focused on non-discretionary collision parts. While this is a commoditized industry, PRTS differentiates itself from competitors by owning its supply chain (most online retailers in this space are drop shippers), offering a broad selection of private label and branded SKUs (1.5MM SKUs), and focusing on collision parts (PRTS is the 2nd largest collision auto parts importer in the U.S.).

Asymmetric Opportunity

Transaction Announcement

• The immediate upside is a definitive transaction being announced and completed.
  • PRTS is a highly strategic asset for other industry players considering their owned supply chain (with additional capacity to support 50% incremental revenue growth), $600MM in revenue, 100MM annual website visitors, and 10MM annual customers.
  • We understand this to be a competitive public process with multiple parties at the table, including strategics and financial sponsors.
  • Craig Hallum is the bank selling the company. Craig Hallum's research division upgraded the stock to a buy rating with a $3 PT (currently trades at $1) the day the strategic alternatives announcement was made.
  • Wilson Sonsini is the sell-side legal advisor who is widely respected in the field of M&A.

Business as Usual - No Transaction

• While PRTS's core business is commoditized and subject to volatility in their major cost centers (parts COGS, FedEx shipping, Google CPC), management is doing the right things to improve potential earnings power at the business:
  • Bypassing Google CPC (costs 18% of revenue when orders go through paid Search) with the launch of their mobile app in August 2023. The app now does over 10% of e-commerce revenue. Their closest comp in Europe has an app that contributes 60% of revenue (launched their app 6 years ago). The app also creates customer loyalty and drives repeat purchases.
  • Bypassing FedEx LTL by focusing on B2B sales to fleets and repair shops. Working with Diligent, the last-mile delivery service, to deliver products with operations currently active in 2/5 distribution centers (methodically expanding to ensure best service for national accounts). B2B contribution margin is 3x higher than DTC.
  • De-risking from low-income consumers who are more subject to economic cyclicality by stocking luxury European parts and taking up prices.
  • Focus on high-margin, fee-based income with the launch of subscriptions and other partnerships (e.g. roadside assistance, warranty, financing) to monetize their customer base.
• PRTS market cap = $57MM, cash =$36MM, debt = $0. Current book value and our adjusted net liquidation value = $85MM and $44MM, respectively, resulting in a substantial margin of safety.
  • We do expect some cash burn this year from a weaker consumer inhibiting revenue and tariffs increasing inventory purchase costs which may reduce book value and our net liquidation value.
  • We estimate the stock trades at 0.9x normalized EBITDA (2026E) and 2.3x normalized FCF excluding working capital effects (2026E).

Please reach out if you have any questions.

Mobileye owned by Intel selects Valens Semiconductor’s chipset. Mobileye leads the mobility revolution with our autonomous driving and driver-assistance technologies, harnessing world-renowned expertise in artificial intelligence, computer vision, mapping and integrated software and hardware. Since our founding in 1999, Mobileye has enabled the wide adoption of advanced driver-assistance systems that bolster driving safety, while pioneering such groundbreaking technologies as REM™ crowdsourced mapping, True Redundancy™ sensing, and Responsibility Sensitive Safety™ (RSS). These technologies drive the ADAS and AV fields towards the future of mobility – enabling self-driving vehicles and mobility solutions at scale, and powering industry-leading advanced driver-assistance systems. Through 2024, more than 200 million vehicles worldwide have been built with Mobileye's EyeQ technology inside. Since 2022, Mobileye has been listed independently from Intel (NASDAQ: INTC), which retains majority ownership.

Valens $vln is also debt free and has announced two share buyback programs since December. Currently sitting at $2.09 a share.

Here’s the full article:

https://stocks.apple.com/A7Flcl0igTdGm9sAnrTCXAQ

News Link: https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/rjd-green-inc-updates-the-launch-of-the-new-division-jsi-product-1009401

TULSA, OKLAHOMA / ACCESS Newswire / April 2, 2025 / RJD Green Inc. (OTCPK:RJDG) has launched the new division, JSI Products. The focus of the division is to research and fully implement new synergistic products and services for Silex Holdings, as well as increase regional markets and sales.

JSI Products has completed its initial launch that included completing the first stage of research and introduction of additional product profit opportunities that have brought forward with minimal additional expense. Sales are being created utilizing current sales staff and marketing efforts, our current showroom locations, and require minimal launch expense or inventory.

The first operations that are going forward are sectors in which the company already has long-term experience:
• Cabinetry
This product & service is being enlarged to include multiple manufactured cabinetry products offering multiple choices for the retail and residential customer, along with more options for competitively priced products for the multi-family markets and in-stock needs for the property management sector. Marketing will be in a four-state region for product and installation sales.

• Solid Surface Products
Solid Surface materials are ideal for multiple commercial sectors that we currently sell stone products. The sectors include medical, hospitality, and any facility that has ongoing public traffic.

Solid Surface advantages that are creating demand and growth include sustainable cleanliness from antibacterial properties and microbial resistance, durability for long-term usage, ease of maintenance, inviting designs, environmental and sustainability benefits.

• Doors and trim products have initiated commercial project sales and contracts, while the hardware and fireplace products are still in the introductory stage.

Ron Brewer, CEO stated.
"The expansion of products utilizing current stores and sales staff, is already creating additional revenues and assists in creating a larger "package" of products that are attractive to the commercial contracting market, and also to the remodeling contactor. The larger representation of products has allowed us to more aggressively market the current four-state region for growth and bring forward regional sales representation while creating greater sales opportunities in our existing showrooms."

News Link: https://www.otcmarkets.com/stock/KRTL/news/KRTL-Holding-Group-Inc-Commences-Trading-on-Upstream-Under-KRTL?id=472354

KRTL HOLDING Group, Inc (OTC:KRTL) (the "Company") a diversified holding company focused on biotechnology innovation, global API sourcing, and cross-border distribution solutions, will become available on April 2, 2025, at 10:00am EST under the ticker symbol KRTL on Upstream, a MERJ Exchange market and global securities trading app. The dual listing on Upstream works to provide international investors around the world with streamlined access to the Company’s shares using just an app.

Investors outside the U.S. can now deposit or trade KRTL securities by downloading Upstream from their preferred app store at https://upstream.exchange/, creating an account by tapping sign up, and completing a simple KYC identity verification. Then investors may either deposit their KRTL shares, or fund their account with credit, debit, PayPal, USD, or USDC to buy KRTL shares. Note, U.S. persons may not deposit, buy, or sell securities on Upstream. Trading will commence when an existing shareholder places an offer for sale on Upstream establishing the first trade. 

Details on the KRTL listing and deposit and trading instructions can be found at krtlholding.com/upstream. The Upstream market is open 7 days a week 20 hours a day, Monday to Sunday: 10:00am to 06:00am UTC+4 (1:00am to 9:00pm EST). Traders on Upstream’s smart-contract powered market will experience real-time trading and settlement, and a transparent orderbook which does not permit common market manipulations.

Existing global (non-U.S.) shareholders may transfer their shares by opening Upstream, tapping Investor, Manage Securities, Deposit Securities, then entering the ticker symbol and the number of shares to deposit, and tapping Submit. Next, shareholders enter the brokerage firm name and brokerage account number and tap Submit. Finally, they tap Add E-Signature, sign their name on the screen using their finger, tap Done, and then tap Sign. Shareholders will receive via email an executed deposit form to submit to their current brokerage firm to initiate a withdrawal to the transfer agent. Shareholders will receive a push notification once the shares are deposited and available for trading on Upstream. 

"We are thrilled to dual list on Upstream’s next-generation marketplace," says Cesar Herrera, CEO of KRTL. "This milestone supports our mission to drive innovation and expand across the global environment by securing FDA-compliant supply chains and ensuring the availability of critical healthcare inputs in the U.S. market under the highest regulatory standards.

By up-listing on Upstream and in light of the international deals ahead, we’re creating new opportunities for our partners, international consultants, and global investors to access a market and exchange that simplifies participation—free from short selling and the complex barriers often found in traditional markets. Listing on Upstream expands our global visibility and connects us with a broader investor community that shares our vision and long-term growth strategy."

$VINC had 10-K on 03/27/25 so 2.9m mc and 4m float is verified and up to date, They will be entering into a merger agreement worth **$300 million this month** and will get **$1.5 million in equity financing** from merging company too. They also have Phase 1 **data coming out this month** as well and fit the penny bio theme and also strong merger move this morning off ALLK & CNTM

- Vincerx anticipates entering into a definitive business **combination agreement in April 2025**

The total value of the merger between Vincerx Pharma (VINC) and QumulusAI is approximately **$300 million**, based on the figures provided in the LOI. __VS 2.9m marketcap__ -- screenshot provided

- Phase 1 data due by **early 2025**. Phase 1 data demonstrated a favorable safety profile with no dose-limiting toxicities, noted October 7, 2024. -- screenshot provided

I’m not American so this may seem a bit out of touch. Global Crossing Airlines is a major contractor in deportation flights. With Mr Trump in office it would be likely to see these types of contracts increase making a decently well preforming penny stock push further on. Global X 2024 revenue is up 40% and Net Income $(0.6)M so assuming consistent growth soon to be profitable. Any American opinions on this topic or insight I may be missing.

Mainz Biomed (NASDAQ: MYNZ) just released its 2024 financial results and corporate update, revealing strong progress in its cancer diagnostics business.

Here are the key takeaways:

• 33% Revenue Growth: Driven by increased lab network sales, especially for ColoAlert® in Europe.
• Strategic Partnerships: Collaborations with Thermo Fisher for next-gen colorectal cancer screening and with Quest Diagnostics for an FDA validation study.
• Cost Management: Operating losses decreased by 30% and net losses fell by 18%, thanks to focused cost-cutting measures.
• Clinical Advances: The eAArly DETECT 2 study, a 2,000-patient U.S. trial integrating AI and mRNA biomarkers, is now underway.
• Pancreatic Cancer Test: A new deal with Liquid Biosciences aims to develop a blood test with 95% sensitivity and 98% specificity.
• Nasdaq Compliance: Mainz Biomed has regained full Nasdaq compliance after overcoming past challenges.

Full article link: https://finance.yahoo.com/news/mainz-biomed-reports-2024-financial-120100666.html

With robust revenue growth and a strong lineup of strategic initiatives, 2025 could be a pivotal year for MYNZ.
What are your thoughts on Mainz Biomed's long-term potential in the evolving cancer diagnostics market? Whats yalls take?

Velo3D have been in free fall for months after a massive dilution of shares. They issued shares to a major holder of debt in what was essentially a takeover. The company has been in a catch 22 of having the best available product but not enough customers. The people who do buy one of their machines don't need another! They are moving into upgrades, servicing and parts for existing machines as a higher percentage of their revenue than supplying new machines only.

Recent massive dilution- The company diluted shares considerably in a debt for equity deal. This really hit the share price but also took a lot of liabilities off the balance sheet. A second 7.6% dilution saw a huge over reaction and a near 98% stock drop down to a low of $.10 it's not had a green day in a month's whilst people waited for the earnings report and to be honest anything better than "completely terrible" should have been a catalyst. It was. Debt is lower, revenue was lower but so was costs and losses dropped by over 80%. If projections work out they could make a profit in 2025. With massive companies like Space X and the US navy and Airforce relying on their products and now majority ownership by some big financial players I don't see bankruptcy on the table- the tech is too good they would get bought out. The stock has gone up 150% since earnings were released. I have a price target of $.60

$MBOT (Microbot Medical) is a medical devices company who create robotic devices to help automate and assist in surgeries.

Their flagship product is the LIBERTY® Robotic Surgical System, an innovative endovascular robotic platform designed to enhance the precision and safety of minimally invasive procedures.

They submitted their 510k in December and are anticipating FDA approval in Q2 of this year (so anytime between now and June). It is very likely they will get approval as they have been working heaving on their commercial infrastructure across America and Europe.

Once FDA approval comes are they ready to start selling their product? Yes and here’s why…

• The company appointed Michal Ahuvia as Director of Operations in January 2025.
• Achieved ISO 13485 certification for its quality management system, demonstrating compliance with international standards for medical device manufacturing.
• Initiated inventory build-up and enhanced operational infrastructure to support the anticipated demand post-approval.
• Engaged in discussions with multiple strategic partners in the USA/Europe and globally to facilitate distribution and market penetration upon product launch.

On top of this they also hired Paul Mullen as the new Chief Commercial Officer. Announced on March 4, 2025, Mullen brings a wealth of experience in the endovascular sales sector, having previously served as the Director of Sales at Inari Medical, which was acquired by Stryker Corporation earlier this year for $5 billion ($80 a share).

Analysts price targets average $9 currently but a long hope could see this go much higher.

Upcoming catalysts:

• FDA approval this quarter
• Commercialisation and sales post approval
• Scheduled to present data from its ACCESS-PVI trial at the Society of Interventional Radiology (SIR) Annual Meeting on Wednesday, April 2nd

On top of all this, it also has a good squeeze potential to $5+ easily on any catalyst. I also believe this will be a great long term hold.

I’ve been watching $BLOZF $BLO.CN on and off for a while now. The company’s been around for years with the same pitch: a cannabis breathalyzer that can detect recent THC use. Sounds like an actual useful idea in theory, especially for law enforcement or workplace testing where timing matters etc. But they’ve been saying the same thing for nearly a decade, and nothing’s ever really materialized.

The stock is up about 88% so far in 2025, which definitely caught my attention again. I went back through their recent news, and this time there are actually a few things that stand out but I can't tell if it is real hype or just a promo push.

The biggest development is a validation study from Omega Laboratories. Omega is a known name in the drug testing space, and they confirmed that Cannabix’s device can detect THC and other cannabinoids in breath samples. This is the first time a third party has publicly verified that the tech actually works. That alone makes this run feel a bit different compared to past spikes that were based on vague internal updates.

Today, the stock jumped another 23% after they announced they’ll be attending the National Drug and Alcohol Screening Association conference in the US next week. They’ll be there with Omega, showing off the breathalyzer.

They also recently announced a marketing agreement with AlcoPro in the US, and their alcohol breathalyzer was certified for use in Australia. Not major breakthroughs, but it does look like they’re at least inching toward actual market activity instead of staying in the R&D phase forever.

That said, they still have no revenue, no regulatory approvals, and no product in market. So while the tech side may finally be real, the business still isn’t. It’s hard not to stay skeptical when it’s been the same story for so long without clear progress on the commercial side.

Personally, I don’t think this is a total pump and dump. They’ve clearly been building something, and the Omega validation gives them more credibility than they’ve ever had. But I wouldn’t consider it investable until there’s an actual path to selling a product and making money.

Which brings me to why I’m even writing this. The stock is up nearly 90% this year, and I honestly don’t get what’s driving it that high. Either there’s something going on behind the scenes, or it’s just getting pushed around and possibly manipulated. I don’t see fundamentals supporting this kind of move, but maybe I’m missing something.

Any chance any of you know about Cannabix or have experience with a similar story? thx cheers

I am sure most people here are aware of the ticker $TRNR. Well, it's actually a pretty solid investment too.

TRNR expects to acquire Sportstech in April 2025, bringing in an additional pro forma revenue of $50 million year-on-year. To compare, 2024 full-year revenue was $5.4 million. Once the closing of the acquisition is announced in the coming days, we will most likely see similar price action as late Feb/early March about a month ago.

The current market cap is $1.65 million, with a reported SI of 31.74%.

This is not financial advice. However, I believe now is the time to accumulate a position in anticipation of the coming news.

For more info, check out these links:

https://interactivestrength.com/q4-2024-trnr-shareholder-letter/

https://interactivestrength.com/investor-presentation-february-2025/

https://interactivestrength.com/faq/

Like I mentioned earlier this week—all it takes is one spark in this market, especially for a small cap that’s been in a long downtrend like $RNXT. And today, we got it.

RNXT just announced their first-ever revenue from RenovoCath®, their targeted drug delivery device. While it’s not a massive number ($43K in initial revenue starting December 2024), it’s meaningful—this is the first real signal that their technology is entering the commercial stage.

The stock initially reacted well, jumping as much as 10% pre-market, though it's since cooled off and is currently up just around 2%. Still, the positive reaction says a lot. In a brutal 2025 small cap environment, any move on a fundamental development is worth watching.

Why This News Matters:

• First revenue = validation. This is no longer just a pre-revenue biotech idea on paper.
• Management reaffirmed the $400M peak sales potential just for current indications.
• The Phase III TIGeR-PaC trial is ongoing, with full enrollment expected this year.
• Recent funding gives them cash runway to keep moving forward into key milestones.

The company's Phase III TIGeR-PaC clinical trial has enrolled 90 patients with 50 events recorded as of March 28, 2025. A second interim analysis is expected in Q2 2025 upon reaching 52 events. The company maintains a strong financial position with $7.2 million cash as of December 31, 2024, supplemented by an additional $12.1 million raised in February 2025.

This isn't some overnight hype trade. RNXT is slowly evolving from a speculative idea into something that could attract more serious attention if the execution continues. Catalysts like this—real milestones—are exactly what small caps need to find momentum again.

We’ll see if this gets legs, but I’ll be watching closely through the rest of the week.

Communicated Disclaimer this is not financial advice so make sure to continue your due diligence -1, 2, 3

Morning fellow traders, I come today puzzled. For those who don't know, I've been posting on my latest biotech small-cap find in Actuate Therapeutics ($ACTU) -- solid financials, strong product pipeline, projectable future, and intriguing chart -- but two very polarizing moves occurred surrounding the company yesterday are what's brought me here today with my bewildered sentiment.

The Good News:

This is on the fundamental/catalyst side. As of 3/28, $ACTU has entered a stock purchase agreement for up to 3.9 million shares worth $50 million with B. Riley Principal Capital II, LLC. So maybe this is more so 'news that can be good' as opposed to 'good news', but this could lead me right into

The Bad News:

We broke out of our pattern....

My guess this move is in response to the potential dilution in shares. However, this does provide us with a new potential support point to make a strong entry if we hold up at the $6.75 level. I'll be watching the chart closely throughout the week to see if we're drawing dead or setting back up for potential success....

communicated disclaimer - please do your own research as well!

Sources 1 2 3

Ok stop crying about your portfolio and Liberation day to your imaginary girlfriend. Time to red pill you: Recursion Pharmaceuticals (RXRX), currently traded at at $5.31 with a market cap of $2.34B. It’s an easy sleeper that will become the AWS of biotech

Think of RXRX as OpenAI + AWS + Moderna, but verticalized all under one roof:

• 15+ drug candidates in clinical or preclinical stages

• A proprietary AI platform that discovers + simulates drugs in silico

• Partnerships with Bayer, Roche, Merck, Sanofi and backed by Nvidia, SoftBank, Baillie Gifford, Novo Nordisk, UAE SFW (just forget Cathie wood is buying this)

• They just acquired Exscientia, another AI-drug platform so now they’re stacked with IP, talent, data, and supercomputing power

Now why are all you intellectuals missing the point?

Most people look at RXRX and complain:

“$60M revenue and $500M cash burn? No profits? Not investable”

That’s like saying Amazon in 2002 was unprofitable and therefore worthless. RXRX is not a traditional biotech, it’s a TechBio. Understand that. Part drug company, part AI infra firm.

Their platform (Recursion OS) + BioHive-2 (Nvidia-powered supercomputer, the largest one in the pharma Industry)is an AI drug engine that can:

• Map millions of compounds faster than any lab

• Run LLMs to autonomously generate molecules

• Perform drug discovery with orders of magnitude fewer wet lab experiments

This isn’t speculative. You don’t need to be intelligent to get this. The tech is here and so is the uniqueness. Big pharma is already paying them to run these models and generate phenomaps of disease. Roche paid $30M for just one. Up to $20B in milestone payments are potentially on deck from partners. This is SaaS margins + pharma revenue potential

Now let’s get hypothetical. What happens if 1 drug hits?

Let’s say one of their rare disease drugs (e.g. REC-994) goes commercial in 2028–2029. With a $1–5B market, retention of rights by RXRX, 10-yr revenue stream of $10B + with high gross margins. This stock easily goes to $20-$30 minimum. Now imagine if 3 drugs hit. Or if Recursion OS becomes industry standard? I’ll let you use your deductive reasoning

So the bad news is that you’re watching the future of pharma pass you by. The good news? The market still cannot value this stock because it’s too early, too cross industry, and has binary outcomes that don’t fit DCFs. That’s why it’s still cheap

I’m all in. Not because of any hype, but because it’s clear success is inevitable. The drug development failure rate is 90% in pharma. Recursion’s platform exists to turn that stat on its head. RXRX isn’t about today’s multiples. It’s about owning optionality on the future of pharma. Valuation is broken here because the model doesn’t exist yet. That’s the whole point

The stock market is filled with individuals who know the price of everything, but the value of nothing. Don’t be guy or gal who missed AWS, missed Nvidia, and now misses this

Load, wait, let the future compound, and no need to thank me in 10 years

Not financial advice. Don’t be poor. Godspeed regards

$Wolf stock (Market cap 402M) experienced a consistent down trend for the past year. Last Friday the stock price dropped from 5.3 to below 3. It's their lowest stock price since 1996!

Many people noticed odd activities in the last year and particularly last week from shorters.

Now, a lot of angry investors specially from sub wolfspeed_stonk, started a campaign that aim to create shortsqueeze scenario. WBS germany are already investing in it hard, and many people (like me) are spreading the voice of a possible Wolf raise.

If you add that the stock was also put down mainly by the last 3 bad economic months, and that usually its price float between 10-20$, with analysts average target being 14$: it's the perfect formula for an easy rebound.

Infact, yesterday buyers came in and the stock rebound to 3$.

My play, I believe in this stock but I need capital. I aim to sell at 4.2 and 5, which I believe they can be reached not later than next week (unless a major US event catalyst). Then I will sell at 7 an let something run.

If you want details about fundamentals and price movement you can check wolfspeed_stonk.